Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DISC-3405 · 2 trials · 2 indications
Proportion of participants with treatment-emergent adverse events
Proportion of participants with changes in vital signs
Proportion of participants with changes in physical examinations
Proportion of participants with changes in electrocardiograms (ECGs)
Proportion of participants with changes in clinical laboratory results
Proportion of participants with treatment-emergent adverse events (TEAEs), changes in vital signs, changes in physical examinations, changes in electrocardiograms (ECGs), and changes in clinical laboratory results
| Arm | Type | Description |
|---|---|---|
| Within-participant dose escalation | EXPERIMENTAL | This is an open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405. |
| Name | Type | Description |
|---|---|---|
| DISC-3405 | DRUG | DISC-3405 is administered subcutaneously. |
Inclusion Criteria: 1. Aged 18 years or older at the time of signing the informed consent form (ICF). 2. Meet revised 2022 World Health Organization (WHO) criteria for the diagnosis of PV. 3. Complete blood count values at Screening of HCT \<45% or HCT \<48% if followed by a phlebotomy within 2 wee...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Bomedemstat |
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE2 | Rusfertide |
| Agios Pharmaceuticals, Inc. | AGIO | 1 | PHASE2 | AG-236 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
DISC-3405 is an investigational small molecule being developed by Disc Medicine, Inc. for hematologic conditions. It is being studied in polycythemia vera (PV) and sickle cell disease (SCD). DISC-3405 has received an orphan drug designation from the FDA and remains in clinical development.
DISC-3405 is being studied as a treatment for polycythemia vera, a blood disorder characterized by excess red blood cell production. A Phase 2 open-label study is evaluating the drug in adults with PV. It is investigational and has not been approved for any use.
DISC-3405 targets TMPRSS6, a transmembrane serine protease. By acting on TMPRSS6, the small molecule is designed to influence iron regulation pathways relevant to red blood cell production. This mechanism is being explored in polycythemia vera and sickle cell disease.
DISC-3405 is being developed by Disc Medicine, Inc., a hematology-focused biopharmaceutical company. Disc Medicine trades on the Nasdaq under the ticker symbol IRON. The company is running clinical studies of DISC-3405 in polycythemia vera and sickle cell disease.
DISC-3405 is in Phase 2 clinical development. A Phase 2 open-label study in polycythemia vera is active but not recruiting, and a Phase 1b open-label study in sickle cell disease is recruiting. The drug is investigational and has not been approved by the FDA.
DISC-3405 is being evaluated in two registered studies. NCT06985147 is a Phase 2 open-label trial in polycythemia vera with 60 participants, currently active but not recruiting. NCT07187973 is a Phase 1b open-label trial in sickle cell disease with 24 participants, currently recruiting in the United States.